Senior Scientist Janssen Research and Development, LLC
T-cell redirectors continue to be a promising modality to treat cancer particularly for hematological malignancies. In this presentation we will review the application of key preclinical data in predicting FIH efficacious doses along with the choice of PK/PD approaches and underlying assumptions (empirical and/or mechanistic PK/PD).
Learning Objectives:
Upon completion, participant will be able to appreciate impact of preclinical pharmacology experimental set-ups in influencing FIH efficacious dose projections
This presentation will highlight the strengths and shortcomings of different PK/PD approaches used for FIH efficacious dose projections
The participant will also appreciate the knowledge gaps in biology of T-cell redirection and its impact on FIH efficacious dose projections
.jpg "Nirav Shah, PhD photo")